Oncogenic AKTivation of translation as a therapeutic target.
about
Signaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Targeting translation initiation in breast cancerAkt inhibitors: mechanism of action and implications for anticancer therapeutics.Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells.YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrenceAkt blocks the tumor suppressor activity of LKB1 by promoting phosphorylation-dependent nuclear retention through 14-3-3 proteins.A conserved role of IQGAP1 in regulating TOR complex 1Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein.Conversion of cell-survival activity of Akt into apoptotic death of cancer cells by two mutations on the BIM BH3 domain.Translational control in cancer etiology.Cell survival and apoptosis signaling as therapeutic target for cancer: marine bioactive compounds.Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.Contribution of CFTR to alveolar fluid clearance by lipoxin A4 via PI3K/Akt pathway in LPS-induced acute lung injury.Polysome Profiling Links Translational Control to the Radioresponse of Glioblastoma Stem-like Cells.Butein Inhibits Angiogenesis of Human Endothelial Progenitor Cells via the Translation Dependent Signaling Pathway.Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover.Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV.Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.Translational control of the fibroblast-extracellular matrix association: An application to pulmonary fibrosis.Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.Combination of phosphatidylinositol 3-kinases pathway inhibitor and photodynamic therapy in endothelial and tumor cells.Sigma1 Pharmacology in the Context of Cancer.Revealing nascent proteomics in signaling pathways and cell differentiation.A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.
P2860
Q26764899-914B5643-03C0-41BC-B799-6C8D94CCB761Q26775940-567F8CBC-A291-46A1-8DEA-0D5347A1057CQ27027284-E5A5062E-EF6F-464E-9FBA-9BA857829BEBQ33641026-E1D9AF15-4291-4D9E-8B85-E71B8B741E45Q33888946-5BDC73AF-E28C-4E73-9305-F33624177872Q34238619-6F305B4E-F720-49CD-B461-D6FCD7005D1BQ35096727-88177E66-7E8D-46D1-9FFB-0AB16FEECECFQ35781327-DCFD6F92-9E0E-46CE-A8C7-81867F072800Q35964171-C3FA135E-D1AB-4E03-952C-4E6EF509FDA2Q35990028-6597EACE-9CFA-4B3E-BE9E-2B80A028783EQ36237322-DC6F26D8-40E9-4F23-BBEB-1E769E0D9C63Q36293800-B186135C-0378-4CEC-ACF3-5911C7B8DF6DQ36555212-8E087782-8F5E-4A78-AB30-3D58DDCAEE16Q36655944-CA4F4F4D-639F-4987-A47E-974CF2DF60C4Q36865078-AD5D6EB5-4C23-449F-8B99-8EC3292A46FDQ36879136-6709CF1E-EB72-4F41-9EC7-A0FF63B98968Q36899582-02845C9F-E4F4-4BC5-B987-E7AE05197519Q36917797-99DE53DE-C260-409D-BD80-49C57CFD98F4Q36948553-5658A94F-BAF3-494E-B827-3185B8952D33Q37030911-EBDD1FAF-C9FF-452F-82AB-BBC0DA5B6545Q37587991-15D31DD9-16D4-40A0-959F-7C579DCEB2DFQ37619695-9512785C-F675-4AD1-B991-C8D3702FD66BQ37626177-196D4DDC-2D1A-458B-B84E-F6BA9F3A0AC5Q37660329-777C1A29-4ED8-41A6-AA92-991D6B613236Q38017247-47D981A4-08F3-4DF0-B33B-3EBF78A71F4AQ38073761-25CDCA5C-97D7-4DDE-B812-81DB5FAABFFEQ38260151-BDB0D362-A727-43BE-8D6E-88AAFFC7B9BAQ38715693-0612BE37-20A8-4968-85C0-540BEB55A366Q39166561-873CB08A-1527-4972-8852-CDB8550F7DCEQ39185396-1DF8CBF1-9CEC-4407-BEC0-BA7643D7EDE6Q39208340-B707DEEA-ABA4-4DE4-B771-78B33334996FQ39364150-8DC7FDE9-6F08-4382-BCFE-D4C61AFA6242Q39458668-38D9AA04-7456-4E2D-9E2D-74BC81D25104Q52731168-92233ABA-79F6-4141-B292-D62E375CC3B5Q53704366-14E7EE06-3BF0-44F5-90EB-9343ECADD8A6
P2860
Oncogenic AKTivation of translation as a therapeutic target.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oncogenic AKTivation of translation as a therapeutic target.
@en
Oncogenic AKTivation of translation as a therapeutic target.
@nl
type
label
Oncogenic AKTivation of translation as a therapeutic target.
@en
Oncogenic AKTivation of translation as a therapeutic target.
@nl
prefLabel
Oncogenic AKTivation of translation as a therapeutic target.
@en
Oncogenic AKTivation of translation as a therapeutic target.
@nl
P2093
P2860
P921
P356
P1476
Oncogenic AKTivation of translation as a therapeutic target.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.241
P407
P577
2011-07-19T00:00:00Z
2011-07-26T00:00:00Z